Ironwood Pharmaceuticals, Inc. (IRWD)

NMS – Real vaqt narxi. Valyuta: USD

4.09

-0.08 (-1.92%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.10

+0.01 (0.29%)

Bozor oldidan: May 13, 2026, 8:33 AM EDT

08.05.2026

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).

08.05.2026

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

08.05.2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

07.05.2026

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.14 per share a year ago.

07.05.2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance. “Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-y.

04.05.2026

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (TPN) in the treatment of short bowel syndrome (SBS). Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of life, reduce line infections and lower the risk of thrombosis. The majority (46.4%) identified reducing the number of days per week on TPN as a priority attribute of future therapies. An additional 30.1% prioritized reducing TPN hours per day, while fewer respondents (11.3%) prioritized reducing TPN volume.

23.04.2026

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) f.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

04.05.2026

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

23.04.2026

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) f.

04.03.2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals, Inc. (IRWD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Videolar

No Data

Press-relizlar

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Videolar

No Data

Press-relizlar

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Search stocks

Ironwood Pharmaceuticals, Inc. (IRWD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Videolar

No Data

Press-relizlar

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Videolar

No Data

Press-relizlar

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference